Clinical Trial Update: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 open-label study evaluating the safety, tolerability, and pharmacokinetics of oral NNZ-2591 in Angelman syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• NNZ-2591 (NNZ-2591)

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Angelman Syndrome | Phase 2 | Status: COMPLETED